CANCER BIOMARKERS MARKET ANALYSIS

Cancer Biomarkers Market, By Biomarker Type (CA 125, HER2, EGFR, CD20, BRAF, Calcitonin, Others), By Cancer Type (Breast Cancer, Lung Cancer, Prostate Cancer, Kidney Cancer, Liver Cancer, Head & neck Cancer, Non-small Cell Lung Cancer, Other Cancers), By Profiling Technology (OMICS Technology, Imaging Technology, Immunoassays, Cytogenetics, Others), By End User (Hospitals, Specialty Clinics, Diagnostic Laboratories, Academic & Research Institutes, Others), By Geography (North America, Europe, Asia Pacific, Latin America, Middle East and Africa)

Published In : Mar 2024
Code : CMI175
Pages :156
Formats :
Excel and PDF
Industry : Clinical Diagnostic

Key Developments

On March 04, 2024, Synexa Life Sciences, a global clinical laboratory services supplier for the biopharma sector, announced the addition of the Olink Target immunoassays and the Olink Signature Q100 instrument to its comprehensive suite of biomarker discovery platforms
On January 23, 2024, Cleveland Diagnostics, Inc., a clinical-stage biotechnology firm developing next-generation diagnostic tools for cancer detection, announced the closure of USD 75 million in growth capital investment. The financing was spearheaded by Novo Holdings, a renowned global life sciences investor that manages the Novo Nordisk Foundation's assets, with participation from existing investors and a credit facility from Symbiotic Capital.
In June 2023, Invivoscribe, an industry leader in precision diagnostics, announced a collaboration with Complete Genomics, a life sciences business, to develop and market biomarker assays using Complete Genomics' NGS systems. Under the terms of the agreement, Invivoscribe will be in charge of developing biomarker assays, including test controls and supporting bioinformatics tools.
On June 16, 2022, Nonagen Bioscience, a cancer diagnostics company, announced that it had received CE marking for its Oncuria immunoassay for bladder cancer. Oncuria is the first-of-its-kind multiplex urine test for the quantitative detection of 10 biomarkers in urine that are associated with the presence of bladder cancer.
On June 3, 2022, Tempus, a leader in artificial intelligence and precision medicine, announced the expansion of its comprehensive genomic profiling offerings with xF+, a new non-invasive, liquid biopsy panel of 523 genes, focused on pathogenic mutations in cell-free DNA (cfDNA). It can measure blood-based tumor mutational burden (bTMB) and microsatellite instability (MSI), predictive biomarkers for response to various cancer immunotherapies.